How AI and Charter Schools Could Close the Tutoring Gap
The greatest school in history isn't Oxford, Cambridge, Harvard or any other university you know. And no matter how hard you try, your kids won't get in. Why? Partly because it was so selective it only admitted one student — but mainly because it closed in 336 BC. For me, Aristotle's seven-year tutelage of Alexander is the education against which all others should be judged (after all, more than 2,300 years later we still refer to the lone pupil as 'The Great'). It's the ultimate testament to the power of tutoring — a power that artificial intelligence is poised to unlock.
The problem with tutoring is it can't scale. Or it couldn't. Because even as we're besieged by concerns that AI-aided plagiarism is destroying education, we're starting to see evidence that AI-enabled tutoring might supercharge it. Getting the technology right, though, will require lots of real-life experimentation. While there's a limit to how much our traditional public school system allows for this kind of test-and-learn approach, this need creates an opportunity for the country's growing crop of charter schools to make a unique contribution to the future of education.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Inkbit Introduces: Cyclic Olefin Thermosets
A Class of Low-Loss Materials Designed for Radio Frequency and mmWave Applications MEDFORD, Mass., June 16, 2025 /PRNewswire/ -- Inkbit, a MIT spinout pioneering additive manufacturing at the intersection of machine vision and material science, today unveiled a new class of materials available through its exclusive platform. Cyclic Olefin Thermosets (COT) are a class of low-loss dielectric materials, particularly well suited to mmWave applications. "When coupled with our platform, which scales seamlessly from prototyping to production, this class of materials will enable rapid innovation. Opening paths for faster, cost effective iteration, and end-use production across the radio frequency and microwave market space." – David Marini, CEO of Inkbit This launch marks Inkbit's official entry into the antenna systems and wave-guiding component space, offering a powerful alternative to traditional manufacturing of Gradient Index (GRIN) lenses, waveguides, and beam-steering structures. Making Scalable GRIN Lenses a RealityIn traditional workflows, GRIN lenses and dielectric components require multi-step manufacturing, precision machining, or complex assembly of stacked layers, each step introducing variability and imperfections that reduce electromagnetic performance. With Inkbit, these same components can be printed as monolithic parts, eliminating manual assembly while achieving tight control over dielectric gradients and geometries. What Inkbit COT SolvesCOT delivers a long-missing combination of low dielectric loss, thermal stability, and mechanical strength in additive manufacturing. These qualities were previously only possible through high cost, high labor processes. Now, engineers can iterate freely, without compromising material performance or waiting for custom tooling. "Limitations around existing material options and manufacturing processes has meant complex dielectric structures have mostly been an academic curiosity for antenna engineers." said Scott Twiddy, Materials R&D Lead at Inkbit. "We look to change that at Inkbit, with this new class of low-loss polymer that can be processed in high-resolution at a production scale. Engineers can iterate quickly without compromising on performance, utilizing the same materials and process for both development and production." Key Benefits for RF Designers: Low dielectric loss at mmWave frequencies Dimensional stability across high temperatures High print resolution and multi-material compatibility Tool-free fabrication of complex 3D dielectric geometries GRIN lensing validated up to 90 GHz Auto-Generate GRIN Lattices via Inkbit Construct "Iteration is the mother of invention," said Davide Marini, CEO of Inkbit. "With this new class of materials and our production platform, mmWave engineers can now design, test and deploy advanced dielectric components at a much higher iteration rate than was ever possible." Together with our VCJ platform, COT enables digitally-driven, scalable manufacturing of next-gen RF and microwave components, ideal for telecom, aerospace, and defense applications. Discover Inkbit RF Solutions: About InkbitInkbit is an additive manufacturing company located in Medford, Massachusetts. The Inkbit Vista™ system is designed for volume production of complex polymer 3D printed parts. Incorporating a novel technology called Vision-Controlled Jetting (VCJ), Inkbit delivers a multi-material additive manufacturing solution that accelerates the translation of ideas into products. Learn more at Media Contact:Jeff Enslowjenslow@ View original content to download multimedia: SOURCE Inkbit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
Asciminib: High Responses in Second-Line Chronic-Phase CML
Asciminib, a first-in-class BCR - ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line therapy for patients with chronic-phase chronic myeloid leukemia (CML) who had suboptimal responses to earlier therapies. METHODOLOGY: The interim analysis on the single-arm, open-label study, conducted at 85 trial sites in the US, included 101 patients with chronic-phase CML who discontinued a prior TKI due to intolerance or suboptimal responses. Patients were treated with at least one dose of asciminib 80 mg once daily. If BCR - ABL levels were above 1% at week 24, the dose was increased to 200 mg daily, and if BCR - ABL levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. - levels were above 1% at week 24, the dose was increased to 200 mg daily, and if - levels were above 0.1% at 48 weeks, the dose was increased from 80 to 200 mg daily, or from 200 mg daily to 200 mg twice daily, or patients could be taken off the study. Those with any grade 3 or 4 or persistent grade 2 toxicities that were refractory to optimal management were ineligible for dose escalations. Reasons for prior treatment discontinuation were due to a lack of efficacy in 56.4% and intolerance in 43.6% of patients. TAKEAWAY: At week 24, a major molecular response was achieved by 44.4% of patients, with 25.4% achieving a deep molecular response (MR4 or better). In all, 11.1% of patients were given dose escalations upon failing to achieve response milestones. Among 101 patients receiving at least one dose, asciminib was well tolerated by most patients. Asciminib's safety profile was that observed in previous studies, with no new or worsening safety findings observed. Grade 3 and higher adverse events (AEs) included hypertension (8.9 %), thrombocytopenia (6.9%), and neutropenia (5.9%). AEs overall led to dose adjustment or interruption in 26.7% of patients and discontinuation in four patients. IN PRACTICE: 'Asciminib, in contrast with other FDA-approved TKIs, binds to the ABL myristoyl pocket, which may reduce off-target effects compared to the other competitive TKI's,' said first author David Jacob Andorsky, MD, of the Rocky Mountain Cancer Centers, US Oncology Research, Boulder, Colorado. 'Results from ASC2ESCALATE, the first prospective trial of asciminib in second-line chronic-phase CML with dose escalation in patients not achieving response milestones, further support asciminib as a treatment option in second-line chronic-phase CML,' he said. 'The outcomes in patients with asciminib dose escalations continue to be explored, with analyses planned for future presentations,' Andorsky noted. SOURCE: The analysis was presented at the American Society of Clinical Oncology (ASCO) 2025 in Chicago. DISCLOSURES: This study was sponsored by Novartis Pharmaceuticals. Andorsky reported having relationships with AbbVie, AstraZeneca, Celgene, and Novartis.
Yahoo
an hour ago
- Yahoo
Media advisory - Minister Joly to hold a virtual media availability at the Paris Air Show
PARIS, June 16, 2025 /CNW/ - The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, is participating in the International Paris Air Show at Le Bourget in Paris, France, from June 16 to 17. The Minister met with key industry stakeholders in the aerospace, space and defence sectors to highlight Canada's innovative aerospace industry and promote Canada as a top destination for aerospace investment from around the world. Date: Tuesday, June 17, 2025 Time: 3:15 pm (CET) / 9:15 am (ET) Location: virtual This event is for accredited members of the Press Gallery only. Media who are not members of the Press Gallery may contact pressres2@ for temporary access. Stay connected Find more services and information on the Innovation, Science and Economic Development Canada website. Follow Innovation, Science and Economic Development Canada on social media.X (Twitter): @ISED_CA | Facebook: Canadian Innovation | Instagram: @cdninnovation | LinkedIn: Innovation, Science and Economic Development Canada SOURCE Innovation, Science and Economic Development Canada View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
